FIELD: pharmaceutical chemistry.
SUBSTANCE: group of inventions relates to a compound of formula (Ie), specific compounds given in the claims, as well as to their use, method of preparation and pharmaceutical composition based on them. In formula (Ie), the rings Z, Z' are selected from phenylene or pyridylene; Y1 represents either phenyl, pyridyl, pyrazinyl, pyridazinyl or pyrimidinyl, where these groups are optionally substituted with one or two substituents selected from a halogen atom, (C1-C4)alkyl group, cyano group, (C1-C5)alkoxy group, trifluoromethyl group, trifluoromethoxy group or -OH group; Ra, Rb independently represent either a hydrogen atom or a (C1-C4)alkyl group; R and R' independently represent a (C1-C4)alkyl group, -S-(C1-C4)alkyl group, (C3-C6)cycloalkyl group, halogen atom, trifluoromethyl group, -SO2(C1-C4)alkyl group, (C3-C6)cycloalkenyl group, (C1-C5)alkoxy group, -OH group, -CONHRg, where Rg is either a hydrogen atom or (C1-C4)alkyl group, an azetidinyl group, a morpholinyl group or a cyano group; m and m’ are independently either 0, 1 or 2; R’’ represents a hydrogen atom, a (C1-C4)alkyl group optionally substituted with a -COOH group; X2 is -O-, -NH-, -S-, -CO-NH-, -NH-CO-NH-, -NH-CO-, -CH(OH)-, -CH(COOH)NH-, -CH(COOCH3)NH-, -C(OH)(CH2OH)-, , a divalent 5-membered heteroaromatic ring containing either 1, 2, 3 or 4 heteroatoms selected from a nitrogen atom and an oxygen atom, -SO2 -or -SO2-NH-; n is either 0, 1, 2, or 3; Y2 represents a hydrogen atom, a hydroxyl group, a (C1-C4)alkoxy group, COORf, where Rf represents either a hydrogen atom or a (C1-C4)alkyl group, a morpholinyl group, a dihydropyranyl group, , , a -PO(ORf)(OR’f) group, where Rf and R’f independently represent either a hydrogen atom or a (C1-C4)alkyl group, an oxetanyl group, a -Si(CH3)3 group, -NHCOO-(C1-C4)alkyl group or group-CR1R2R3 where the values of R1, R2 and R3 are disclosed in the claims.
(Ie)
EFFECT: aryl-N-aryl compounds useful for fighting infections caused by single-stranded RNA viruses belonging to group IV or V according to the Baltimore classification, namely RSV (respiratory syncytial virus), Chikungunye, influenza and Dengue.
13 cl, 6 tbl, 10 ex
Title | Year | Author | Number |
---|---|---|---|
PHENYL/PYRIDYL-N-PHENYL/PYRIDYL DERIVATIVES FOR THE TREATMENT OF RNA VIRAL INFECTION | 2019 |
|
RU2790838C2 |
ARYL-N-ARYL DERIVATIVES FOR TREATING RNA VIRAL INFECTION | 2019 |
|
RU2815493C2 |
PHENYL-N-QUINOLINE DERIVATIVES FOR TREATMENT OF RNA VIRAL INFECTION | 2019 |
|
RU2805064C2 |
10H-PHENOTHIAZINE FERROPTOSIS INHIBITORS, THEIR PRODUCTION METHOD AND THEIR USE | 2019 |
|
RU2787366C2 |
COMPOUNDS APPLICABLE FOR TREATING AIDS | 2010 |
|
RU2575845C2 |
COMPOUNDS USEFUL AS PESTICIDES, AND INTERMEDIATE COMPOUNDS, COMPOSITIONS AND METHODS RELATED THERETO | 2016 |
|
RU2821715C2 |
MODULATORS OF INTEGRATED STRESS SIGNALING PATH | 2017 |
|
RU2769327C2 |
COMPOUNDS HAVING INHIBITORY ACTIVITY RELATIVELY TO PDE9A AND THEIR PHARMACEUTICAL USE | 2019 |
|
RU2788147C2 |
CONDENSED HETEROARYLS AND THEIR APPLICATION | 2011 |
|
RU2552114C2 |
CHEMICAL COMPOUNDS 637: PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS | 2008 |
|
RU2479584C2 |
Authors
Dates
2023-09-11—Published
2019-07-09—Filed